- Home
- MCR vs DSGN Comparison
MCR vs DSGN Comparison
Compare MCR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- DSGN
- Stock Information
- Founded
- MCR 1989
- DSGN 2017
- Country
- MCR United States
- DSGN United States
- Employees
- MCR N/A
- DSGN N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- DSGN Health Care
- Exchange
- MCR Nasdaq
- DSGN Nasdaq
- Market Cap
- MCR 263.0M
- DSGN 264.4M
- IPO Year
- MCR N/A
- DSGN 2021
- Fundamental
- Price
- MCR $6.17
- DSGN $5.80
- Analyst Decision
- MCR
- DSGN Hold
- Analyst Count
- MCR 0
- DSGN 3
- Target Price
- MCR N/A
- DSGN $7.00
- AVG Volume (30 Days)
- MCR 66.7K
- DSGN 140.3K
- Earning Date
- MCR 01-01-0001
- DSGN 11-07-2024
- Dividend Yield
- MCR 8.52%
- DSGN N/A
- EPS Growth
- MCR N/A
- DSGN N/A
- EPS
- MCR 0.38
- DSGN N/A
- Revenue
- MCR N/A
- DSGN N/A
- Revenue This Year
- MCR N/A
- DSGN N/A
- Revenue Next Year
- MCR N/A
- DSGN N/A
- P/E Ratio
- MCR $16.61
- DSGN N/A
- Revenue Growth
- MCR N/A
- DSGN N/A
- 52 Week Low
- MCR $5.63
- DSGN $2.13
- 52 Week High
- MCR $6.70
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- MCR 27.76
- DSGN 50.20
- Support Level
- MCR $6.30
- DSGN $5.32
- Resistance Level
- MCR $6.42
- DSGN $7.77
- Average True Range (ATR)
- MCR 0.05
- DSGN 0.58
- MACD
- MCR -0.02
- DSGN 0.05
- Stochastic Oscillator
- MCR 1.92
- DSGN 27.57
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income. The fund invests the assets in debt instruments. It invests the assets in corporate bonds of U.S. and foreign issuers, U.S. Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S. and foreign issuers, and debt instruments of issuers located in emerging market countries.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.